{"id":36479,"date":"2018-07-04T09:00:00","date_gmt":"2018-07-04T07:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/"},"modified":"2018-07-04T09:00:00","modified_gmt":"2018-07-04T07:00:00","slug":"ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/","title":{"rendered":"Ipsen annonce la pr\u00e9sentation de nouvelles donn\u00e9es cliniques lors de l\u2019ISPRM 2018 d\u00e9montrant son engagement dans la recherche sur les neurotoxines"},"content":{"rendered":"<p><b>Ces r\u00e9sultats cliniques confirment le soutien d\u2019Ipsen aux patients et \u00e0 la communaut\u00e9 de neuroscience.<\/b><\/p>\n<p><b>Paris (France), 4 juillet 2018\u00a0<\/b>\u2013 Ipsen (Euronext: IPN ; ADR : IPSEY) a annonc\u00e9 aujourd\u2019hui que son portefeuille en neurotoxines ferait l\u2019objet de 13 abstracts lors du 12\u00e8me\u00a0Congr\u00e8s mondial de l\u2019<em>International Society of Physical and Rehabilitation Medicine\u00a0<\/em>(ISPRM), qui se tiendra du 8 au 12\u00a0juillet \u00e0 Paris.<br \/>Les 13 abstracts pr\u00e9senteront des donn\u00e9es en neuroscience qui permettent de faire progresser les connaissances en m\u00e9decine physique et de r\u00e9habilitation fonctionnelle. Ils d\u00e9tailleront notamment les r\u00e9sultats cliniques li\u00e9s au portefeuille d\u2019Ipsen dans la spasticit\u00e9 chez l\u2019adulte (membres sup\u00e9rieurs et inf\u00e9rieurs), chez l\u2019enfant et dans la dystonie cervicale. Par ailleurs, une enqu\u00eate internationale visant \u00e0 \u00e9valuer le fardeau pesant sur les patients atteints de spasticit\u00e9 et sur leur entourage sera pr\u00e9sent\u00e9e. Ces donn\u00e9es r\u00e9elles permettront une meilleure compr\u00e9hension des pratiques cliniques actuelles.<br \/>\u00ab\u00a0Le Docteur\u00a0<b>Alexandre Lebeaut, Vice-Pr\u00e9sident Ex\u00e9cutif, R&amp;D et Chief Scientific Officer, Ipsen\u00a0<\/b>a d\u00e9clar\u00e9 :<em>\u00a0\u00ab\u00a0L\u2019\u00e9dition 2018 de l\u2019ISPRM 2018 verra la plus forte pr\u00e9sence qu\u2019Ipsen ait connu jusqu\u2019\u00e0 pr\u00e9sent, d\u00e9montrant ainsi notre attention particuli\u00e8re \u00e0 faire avancer la recherche sur les neurotoxines. Nous nous engageons \u00e0 accompagner les patients et la communaut\u00e9 de neuroscience sur le long terme, notamment \u00e0 travers des programmes de formation m\u00e9dicale et des symposiums. Nous d\u00e9voilerons \u00e9galement des donn\u00e9es nouvelles concernant la premi\u00e8re neurotoxine botulique recombinante administr\u00e9e \u00e0 un \u00eatre humain, un domaine dans lequel nous avons pour ambition de d\u00e9velopper et de d\u00e9ployer tout le potentiel de notre nouvelle plateforme technologique.\u00a0\u00bb<\/em><br \/><b>Le Professeur Lynne Turner-Stokes, (Cicely Saunders Institute, King<\/b>\u2019<b>s College London, Royaume Uni)\u00a0<\/b>a ajout\u00e9\u00a0:\u00a0<em>\u00ab\u00a0Les r\u00e9sultats de la grande \u00e9tude observationnelle ULIS-III, dont l\u2019objectif est d\u2019\u00e9valuer la pratique clinique en vie r\u00e9elle, feront l\u2019objet d\u2019une pr\u00e9sentation orale. Cette \u00e9tude a d\u00e9montr\u00e9 que la r\u00e9duction de la douleur est un objectif de traitement important et atteignable chez certains patients atteints de spasticit\u00e9. \u00bb\u00a0\u00bb<\/em><br \/><b><u>Pr\u00e9sentations orales :<\/u><\/b><\/p>\n<ul>\n<li style=\"margin-bottom:3px\"><b>Abstract ISPR8-2524<\/b>\u00a0\u2013 FP16 Neuro-Orthop\u00e9die et spasticit\u00e9 \u2013 Part II, Amphith\u00e9\u00e2tre Bleu<br \/>Mercredi 11 juillet 17h40 \u2013 17h50\n<ul>\n<li style=\"margin-bottom:3px\">Botulinum Toxin A in Upper Limb Spasticity Management: Baseline Data from the Upper Limb International Spasticity (ULIS)-III Study<\/li>\n<li style=\"margin-bottom:3px\">Auteur pr\u00e9sentateur\u00a0: Lynne Turner-Stokes<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\"><b>Abstract ISPR8-2530\u00a0<\/b>\u2013 FP16 Neuro-Orthop\u00e9die et spasticit\u00e9 \u2013 Part II, Amphith\u00e9\u00e2tre Bleu<br \/>Mercredi 11 juillet 17h50 \u2013 18h00\n<ul>\n<li style=\"margin-bottom:3px\">Relief of Spasticity-Related Pain with Botulinum Neurotoxin-A (BoNT-A) in Real Life Practice. Post-Hoc Analysis from a Large International Cohort Series<\/li>\n<li style=\"margin-bottom:3px\">Auteur pr\u00e9sentateur\u00a0: Lynne Turner-Stokes<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><b><u>Posters<\/u><\/b><\/p>\n<ul>\n<li style=\"margin-bottom:3px\"><b>Abstract ISPR8-1217<\/b>\u00a0\u2013 02 R\u00e9habilitation consacr\u00e9e aux probl\u00e8mes sp\u00e9cifiques \u2013 Gestion de la spasticit\u00e9, Espace d\u2019exposition, 9-12 juillet\n<ul>\n<li style=\"margin-bottom:3px\">Impact of Spasticity and Botulinum Toxin-A Injections on the Daily Life of Patients and their Caregivers: Results from an International Online Survey<\/li>\n<li style=\"margin-bottom:3px\">Auteur pr\u00e9sentateur\u00a0: Manuel Murie Fernandez<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\"><b>Abstract ISPR8-2146\u00a0<\/b>\u2013 03 \u00c9ducation et formation \u00e0 la r\u00e9habilitation \u2013 Formation m\u00e9dicale continue et d\u00e9veloppement professionnel, Espace d\u2019exposition, 9-12 juillet\n<ul>\n<li style=\"margin-bottom:3px\">Botulinum Neurotoxin-A Usage and Training in Cervical Dystonia &amp; Spastic Paresis: First Results from the Ixcellence\u00ae Network Survey<\/li>\n<li style=\"margin-bottom:3px\">Auteur pr\u00e9sentateur\u00a0\u00a0: Luis Jorge Jacinto<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\"><b>Abstract ISPR8-2147\u00a0<\/b>\u2013 03 \u00c9ducation et formation \u00e0 la r\u00e9habilitation \u2013 Formation m\u00e9dicale continue et d\u00e9veloppement professionnel, Espace d\u2019exposition, 9-12 juillet\n<ul>\n<li style=\"margin-bottom:3px\">Improving Management Practices of Cervical Dystonia and Spastic Paresis: 5 Years\u2019 Experience of Ixcellence\u00ae Network, an Innovative International Educational Program<\/li>\n<li style=\"margin-bottom:3px\">Auteur pr\u00e9sentateur\u00a0: Luis Jorge Jacinto<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\"><b>Abstract ISPR8-2514\u00a0<\/b>\u2013 02 R\u00e9habilitation consacr\u00e9e aux probl\u00e8mes sp\u00e9cifiques \u2013 Gestion de la spasticit\u00e9, Espace d\u2019exposition, 9-12 juillet\n<ul>\n<li style=\"margin-bottom:3px\">Simultaneous Upper and Lower Limb AbobotulinumtoxinA Injections and Guided Self-Rehabilitation Contracts in Spastic Hemiparesis: Baseline Data from the ENGAGE Study<\/li>\n<li style=\"margin-bottom:3px\">Auteur pr\u00e9sentateur\u00a0\u00a0: Jean-Michel Gracies<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\"><b>Abstract ISPR8-2521<\/b>\u00a0\u2013 02 R\u00e9habilitation consacr\u00e9e aux probl\u00e8mes sp\u00e9cifiques \u2013 Gestion de la spasticit\u00e9, Espace d\u2019exposition, 9-12 juillet\n<ul>\n<li style=\"margin-bottom:3px\">Repeated AbobotulinumtoxinA Injections Benefit Walking Speed, Step Length and Cadence in Adults with Spastic Hemiparesis due to Stroke or Traumatic Brain Injury<\/li>\n<li style=\"margin-bottom:3px\">Auteur pr\u00e9sentateur\u00a0: : Alberto\u00a0Esquenazi<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\"><b>Abstract ISPR8-2529<\/b>\u00a0\u2013 02 R\u00e9habilitation consacr\u00e9e aux probl\u00e8mes sp\u00e9cifiques \u2013 Gestion de la spasticit\u00e9, Espace d\u2019exposition, 9-12 juillet\n<ul>\n<li style=\"margin-bottom:3px\">Efficacy and Safety of Early Use of AbobotulinumtoxinA in Adults with Post-Stroke Spasticity: Results from the ONTIME and ABCDE-S Studies<\/li>\n<li style=\"margin-bottom:3px\">Auteur pr\u00e9sentateur\u00a0: Raymond Rosales<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\"><b>Abstract ISPR8-2543<\/b>\u00a0\u2013 02 R\u00e9habilitation consacr\u00e9e aux probl\u00e8mes sp\u00e9cifiques \u2013 Gestion de la spasticit\u00e9, Espace d\u2019exposition, 9-12 juillet\n<ul>\n<li style=\"margin-bottom:3px\">Treatment Frequency for Long-Term Efficacy of AbobotulinumtoxinA Injections: a Phase 3 Study in Patients with Upper Limb Spasticity Following Stroke or Traumatic Brain Injury<\/li>\n<li style=\"margin-bottom:3px\">Auteur pr\u00e9sentateur\u00a0\u00a0: Jean-Michel Gracies<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\"><b>Abstract ISPR8-2546<\/b>\u00a0\u2013 02 R\u00e9habilitation consacr\u00e9e aux probl\u00e8mes sp\u00e9cifiques \u2013 Gestion de la spasticit\u00e9, Espace d\u2019exposition, 9-12 juillet\n<ul>\n<li style=\"margin-bottom:3px\">When Can Maximal Efficacy be Expected with Repeated Botulinum Toxin Injections in Upper Limb Spastic Paresis? An Exploratory Statistical Analysis<\/li>\n<li style=\"margin-bottom:3px\">Auteur pr\u00e9sentateur\u00a0\u00a0: Jean-Michel Gracies<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\"><b>Abstract ISPR8-2547<\/b>\u00a0\u2013 02 R\u00e9habilitation consacr\u00e9e aux probl\u00e8mes sp\u00e9cifiques \u2013 Gestion de la spasticit\u00e9, Espace d\u2019exposition, 9-12 juillet\n<ul>\n<li style=\"margin-bottom:3px\">AbobotulinumtoxinA Injections in Shoulder Muscles: Results from a Real World (ULIS-II) and Phase 3 (AUL) Studies<\/li>\n<li style=\"margin-bottom:3px\">Auteur pr\u00e9sentateur\u00a0\u00a0: Francois Constant Boyer<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\"><b>Abstract ISPR8-2557<\/b>\u00a0\u2013 02 R\u00e9habilitation consacr\u00e9e aux probl\u00e8mes sp\u00e9cifiques \u2013 Gestion de la spasticit\u00e9, Espace d\u2019exposition, 9-12 juillet\n<ul>\n<li style=\"margin-bottom:3px\">Treatment Frequency for Long-Term Efficacy of AbobotulinumtoxinA Injections: a Phase 3 Study in Patients with Lower Limb Spasticity Following Stroke or Traumatic Brain Injury<\/li>\n<li style=\"margin-bottom:3px\">Auteur pr\u00e9sentateur\u00a0\u00a0: Prof Jean-Michel Gracies<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\"><b>Abstract ISPR8-2654\u00a0<\/b>\u2013 08 Troubles musculosquelettiques \u2013 Divers, Espace d\u2019exposition, 9-12 juillet\n<ul>\n<li style=\"margin-bottom:3px\">Results from the First Recombinant Botulinum Toxin (BoNT) Ever to Enter Clinical Development. Outcomes of a First-in-Human Study with Recombinant BoNT\/E (SXN102308)<\/li>\n<li style=\"margin-bottom:3px\">Auteur pr\u00e9sentateur\u00a0\u00a0: Laurent Pons<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/NTgyNzkxZDItYjc5Mi00MmM3LThiNzMtMjU1YjJjNGNjNmI0LTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1233,3556],"tags":[],"class_list":["post-36479","press_release","type-press_release","status-publish","hentry","category-pressrelease-fr","category-corporate-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen annonce la pr\u00e9sentation de nouvelles donn\u00e9es cliniques lors de l\u2019ISPRM 2018 d\u00e9montrant son engagement dans la recherche sur les neurotoxines<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen annonce la pr\u00e9sentation de nouvelles donn\u00e9es cliniques lors de l\u2019ISPRM 2018 d\u00e9montrant son engagement dans la recherche sur les neurotoxines\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/NTgyNzkxZDItYjc5Mi00MmM3LThiNzMtMjU1YjJjNGNjNmI0LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\"},\"headline\":\"Ipsen annonce la pr\u00e9sentation de nouvelles donn\u00e9es cliniques lors de l\u2019ISPRM 2018 d\u00e9montrant son engagement dans la recherche sur les neurotoxines\",\"datePublished\":\"2018-07-04T07:00:00+00:00\",\"dateModified\":\"2018-07-04T07:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/\"},\"wordCount\":967,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/NTgyNzkxZDItYjc5Mi00MmM3LThiNzMtMjU1YjJjNGNjNmI0LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"articleSection\":[\"Communiqu\u00e9 de presse\",\"Corporate\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/\",\"name\":\"Ipsen annonce la pr\u00e9sentation de nouvelles donn\u00e9es cliniques lors de l\u2019ISPRM 2018 d\u00e9montrant son engagement dans la recherche sur les neurotoxines\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/NTgyNzkxZDItYjc5Mi00MmM3LThiNzMtMjU1YjJjNGNjNmI0LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2018-07-04T07:00:00+00:00\",\"dateModified\":\"2018-07-04T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/NTgyNzkxZDItYjc5Mi00MmM3LThiNzMtMjU1YjJjNGNjNmI0LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/NTgyNzkxZDItYjc5Mi00MmM3LThiNzMtMjU1YjJjNGNjNmI0LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen annonce la pr\u00e9sentation de nouvelles donn\u00e9es cliniques lors de l\u2019ISPRM 2018 d\u00e9montrant son engagement dans la recherche sur les neurotoxines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen annonce la pr\u00e9sentation de nouvelles donn\u00e9es cliniques lors de l\u2019ISPRM 2018 d\u00e9montrant son engagement dans la recherche sur les neurotoxines","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen annonce la pr\u00e9sentation de nouvelles donn\u00e9es cliniques lors de l\u2019ISPRM 2018 d\u00e9montrant son engagement dans la recherche sur les neurotoxines","og_url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/","og_site_name":"Global","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/NTgyNzkxZDItYjc5Mi00MmM3LThiNzMtMjU1YjJjNGNjNmI0LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0"},"headline":"Ipsen annonce la pr\u00e9sentation de nouvelles donn\u00e9es cliniques lors de l\u2019ISPRM 2018 d\u00e9montrant son engagement dans la recherche sur les neurotoxines","datePublished":"2018-07-04T07:00:00+00:00","dateModified":"2018-07-04T07:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/"},"wordCount":967,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/NTgyNzkxZDItYjc5Mi00MmM3LThiNzMtMjU1YjJjNGNjNmI0LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","articleSection":["Communiqu\u00e9 de presse","Corporate"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/","url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/","name":"Ipsen annonce la pr\u00e9sentation de nouvelles donn\u00e9es cliniques lors de l\u2019ISPRM 2018 d\u00e9montrant son engagement dans la recherche sur les neurotoxines","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/NTgyNzkxZDItYjc5Mi00MmM3LThiNzMtMjU1YjJjNGNjNmI0LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2018-07-04T07:00:00+00:00","dateModified":"2018-07-04T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/NTgyNzkxZDItYjc5Mi00MmM3LThiNzMtMjU1YjJjNGNjNmI0LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/NTgyNzkxZDItYjc5Mi00MmM3LThiNzMtMjU1YjJjNGNjNmI0LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-nouvelles-donnees-cliniques-lors-de-lisprm-2018-demontrant-son-engagement-dans-la-recherche-sur-les-neurotoxines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen annonce la pr\u00e9sentation de nouvelles donn\u00e9es cliniques lors de l\u2019ISPRM 2018 d\u00e9montrant son engagement dans la recherche sur les neurotoxines"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36479\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=36479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=36479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=36479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}